shr-1222
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 20, 2019 (NCT03870100)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SclerostinINHIBITOR
SOST inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04435158 | Phase 1 | Jul 1, 2020 | Central South University, Hengrui Therapeutics, Inc. |
| NCT03898024 | N/A | Apr 30, 2019 | Central South University |
| NCT03870100 | Phase 1 | Mar 20, 2019 | Central South University, Hengrui Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Central South University | Academic/Hospital | 3 | 1 | 2 | 2019 |
| Hengrui Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2019 |
2 organizations
Page 1 / 1